Evaluating Prognostic Contribution of Lactate on Recovery of Spontaneous Cardiac Activity After Cardiac Arrest

Cardio-respiratory Arrest, Prolactin Clinical Trial

— PROLAC  

Official title:

A Pilot Study Evaluating the PROgnostic Contribution of Venous Lactate for the Recovery of Spontaneous Cardiac Activity, Following an Extra-hospital Cardiac Arrest "PROLAC Study"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03325452
• Other study ID #: 16-AOI-03
• Status: Completed
• Phase: N/A
• Start date: December 19, 2017
• Est. completion date: August 10, 2020

Study information

• Verified date: April 2022
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Incidence of non-hospital cardio-respiratory arrest (ACR) in France is around 40 000 cases per year, with mortality remaining very high, with 75% of patients dying before arrival in hospital. The investigators know some validated predictive factors for recovery of spontaneous cardiac activity (RACS) such as age, no flow (time between ACR and onset of CPR), type of initial electrical activity (FV, TVSP), or the value of CO2 expired.

However, the use of these prognostic criteria in the conduct of CPR maneuvering is in practice limited. Lactate is now a well-known prognostic biological marker used in many pathological conditions such as shock states or the severe traumatized patient. Some data have also demonstrated the prognostic value of lactate on morbidity and mortality after ACR after resumption of spontaneous cardiac activity.

The hypothesis of our study is that the evaluation of the initial lactate in the early cardiopulmonary resuscitation could be a prognostic factor of RACS.

Description:

Incidence of non-hospital cardio-respiratory arrest (ACR) in France is around 40 000 cases per year, with mortality remaining very high, with 75% of patients dying before arrival in hospital. This disease is associated with a high morbidity since today the investigator find less than 5% survival at 1 year with a favorable neurological outcome.

The recommendations of ILCOR 2015 underline in this case the importance of implementing therapeutic measures in the extra-hospital step. Indeed, the survival of ACR patients will depend mainly on the alert delay at the UAS center, the immediate implementation of cardiopulmonary resuscitation (CPR) maneuvers and the early delivery of external electric shock.

The investigators know some validated predictive factors for recovery of spontaneous cardiac activity (RACS) such as age, no flow (time between ACR and onset of CPR), type of initial electrical activity (FV, TVSP), or the value of CO2 expired.

However, the use of these prognostic criteria in the conduct of CPR maneuvering is in practice limited.

Today, none of these prognostic factors allow us to adapt the cardiopulmonary resuscitation maneuvers to the different clinical situations, and it is recognized that a CPR must be carried out for 30 minutes in all cases.

On the basis of these data, it seemed important to investigate other predictive factors for RACS, which would remain simple to implement, and allow case-by-case customization the cardiopulmonary resuscitation.

Lactate is now a well-known prognostic biological marker used in many pathological conditions such as shock states or the severe traumatized patient. Some data have also demonstrated the prognostic value of lactate on morbidity and mortality after ACR after resumption of spontaneous cardiac activity. Unfortunately, all of these studies were carried out intra-hospital. To date, no prospective study has demonstrated the prognostic value of a lactate assay as soon as the pre-hospital medical team arrives and during pre-hospital cardiopulmonary resuscitation.

An experimental study published in the American Journal of Emergency Medicine in 1985, however, suggests that early evaluation of lactate in the course of cardiac arrest may be a valuable prognostic factor. Indeed, in this study on canine cardiac arrest experimental model, Donna et al found that the lactate concentration would reliably predict the no-flow describing an linear increase of lactate as a function of the no-flow duration. If these results can be extrapolated to humans, lactate measurement from the arrival of the pre-hospital medical team could provide an estimate of the no-flow period and therefore a reliable and easily reproducible predictive factor for RACS .

In addition, improvements in biomedical equipment allow us to perform lactate assays directly at the patient's bedside, with reliable results in just 13 seconds.

The hypothesis of our study is that the evaluation of the initial lactate in the early cardiopulmonary resuscitation could be a prognostic factor of RACS.

For this purpose, the investigators propose to carry out a prospective, open, multicenter intervention study in different SMURs in the PACA region, in France.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: August 10, 2020
• Est. primary completion date: August 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male >18 years of age

• Women over 50 years of age (ie, with amenorrhea> 1 year).

• Victim of non-traumatic cardiopulmonary arrest.

• Medical decision to start or continue cardiopulmonary resuscitation.

• Consent of family or person of trust if present (and patient as soon as possible).

• patient affiliated to the social security

Exclusion Criteria:

• Refusal of family or trusted person to participate in the study

• Pre-paramedical management with use of adrenaline and protection of the airways

• Use of the intraosseous line from the outset or after failure of the peripheral venous pathway by the medical team outside hospital

• Minor Patient

• vulnerable patient under legal protection (guardianship or curators)

Related Conditions & MeSH terms

• Apnea
• Cardio-respiratory Arrest, Prolactin
• Heart Arrest

Intervention

Biological:
• venous lactate
value of venous lactate

Locations

Country	Name	City	State
France	CHU de Nice	Nice	Provences Alpes Cote d'Azur

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	venous lactate	The main evaluation criteria will be the value of the venous lactate that was measured during insertion of the peripheral venous line at the arrival of the medical team (= T0) in patients in cardiac arrest	at baseline
Secondary	Initial value of capillary lactate	to compare with the initial venous lactate value measured at the peripheral venous laying	at baseline
Secondary	The no-flow	This data will be obtained by interrogating the witnesses present during the cardiac arrest.	at baseline
Secondary	The kinetics of capillary lactate	to evaluate by the variability of capillary lactate levels	at time = 10 minutes
Secondary	The kinetics of capillary lactate	to evaluate by the variability of capillary lactate levels	at time = 20 minutes
Secondary	The kinetics of capillary lactate	to evaluate by the variability of capillary lactate levels	at time = 30 minutes